

## Bibliography:

1. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements*. 2013;3(1).
2. Obrador GT, Tonelli M. Early Detection of Chronic Kidney Disease. UpToDate. Published February 9, 2024. Accessed March 11, 2024. [https://www.uptodate.com/contents/early-detection-of-chronic-kidney-disease?search=ckd%20screening&source=search\\_result&selectedTitle=1%7E24&usage\\_type=default&display\\_rank=1#H899786122](https://www.uptodate.com/contents/early-detection-of-chronic-kidney-disease?search=ckd%20screening&source=search_result&selectedTitle=1%7E24&usage_type=default&display_rank=1#H899786122).
3. *Frequently Asked Questions About GFR Estimates*. National Kidney Foundation. 2022. [https://www.kidney.org/sites/default/files/441-8491\\_2202\\_faqs\\_aboutgfr\\_v5.pdf](https://www.kidney.org/sites/default/files/441-8491_2202_faqs_aboutgfr_v5.pdf).
4. Podestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. *Biomedicines*. 2023;11(2):279. Published 2023 Jan 19. doi:10.3390/biomedicines11020279
5. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. *Kidney Int Rep*. 2022;7(7):1463-1476. Published 2022 May 5. doi:10.1016/j.ekir.2022.04.094
6. Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. *Curr Diab Rep*. 2022;22(1):39-52. doi:10.1007/s11892-021-01442-z
7. Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed March 7, 2024.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int*. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021[PubMed 34556256]